palbociclib

Can Pfizer's new breast cancer med really cruise to $4B and beyond?
Can Pfizer's new breast cancer med really cruise to $4B and beyond?
Fierce Pharma Marketing
Pfizer
breast cancer
palbociclib
Flag link:
Pfizer breast cancer drug gets early FDA approval
Pfizer breast cancer drug gets early FDA approval
Yahoo/AP
Pfizer
palbociclib
HER-2 postive breast cancer
breast cancer
FDA
Flag link:
FirstWord Lists – The drugs that will shape 2015
FirstWord Lists – The drugs that will shape 2015
First Word Pharma
Harvoni
Viekira Pak
Gilead Sciences
AbbVie
alirocumab
evolocumab
Amgen
Regeneron
Sanofi
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Novartis
CTL019
Zarxio
Pfizer
palbociclib
Saxenda
Trulicity
Afrezza
MannKind
Eli Lilly
Novo Nordisk
LCZ696
Toujeo
Breo Ellipta
GED-0301
Celgene
BiogenIdec
Flag link:
Pfizer nears a new dawn in oncology with AstraZeneca in the rearview
Pfizer nears a new dawn in oncology with AstraZeneca in the rearview
Fierce Biotech
Pfizer
AstraZeneca
breast cancer
palbociclib
Flag link:
Drug Data Dump: Pfizer, Biogen, AbbVie
Drug Data Dump: Pfizer, Biogen, AbbVie
Forbes
Pfizer
AbbVie
Biogen Idec
anti-LINGO-1
optic neuritis
palbociclib
breast cancer
Elagolix
endometriosis
Flag link:
Pfizer, FDA in talks on prescription details for key breast cancer drug
Pfizer, FDA in talks on prescription details for key breast cancer drug
Yahoo/Reuters
Pfizer
FDA
palbociclib
breast cancer
Flag link:
5 Potential Blockbuster Drugs Set To Launch In 2015
5 Potential Blockbuster Drugs Set To Launch In 2015
Investors.com
Amgen
Regeneron
evolocumab
alirocumab
Alexion
asfotase alfa
Novartis
LCZ696
Pfizer
palbociclib
Flag link:
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review
Yahoo
Pfizer
palbociclib
FDA
advanced breast cancer
Flag link:
The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
In the Pipelline
palbociclib
Pfizer
Flag link:
Pfizer Announces Submission of Palbociclib New Drug Application to the FDA
Pfizer Announces Submission of Palbociclib New Drug Application to the FDA
Yahoo
Pfizer
palbociclib
FDA
breast cancer
Flag link:
5 Things Pfizer Inc.'s Management Wants You to Know
5 Things Pfizer Inc.'s Management Wants You to Know
Motley Fool
Pfizer
stock buybacks
palbociclib
generics
M&A
emerging markets
Flag link:
FirstWord Lists: Pharma's biggest pipeline drugs
FirstWord Lists: Pharma's biggest pipeline drugs
First Word Pharma
pipelines
nivolumab
Pembrolizumab
evolocumab
palbociclib
cancer
breast cancer
Pfizer
Bristol-Myers Squibb
Merck
Amgen
Flag link:
[video]Could This be Pfizer's Best Incoming Drug?
[video]Could This be Pfizer's Best Incoming Drug?
Motley Fool
Pfizer
palbociclib
breast cancer
Flag link:
Pfizer seeks early approval for breast cancer drug
Pfizer seeks early approval for breast cancer drug
Yahoo/AP
breast cancer
Pfizer
palbociclib
Flag link:
Pfizer’s Pipeline: 2 Drugs That May Drive Future Revenues
Pfizer’s Pipeline: 2 Drugs That May Drive Future Revenues
Wall St Cheat Sheet
Pfizer
palbociclib
breast cancer
RN316
Flag link:
6 Drugs That Could Move the Pharma Market
6 Drugs That Could Move the Pharma Market
Wall St Cheat Sheet
Gilead Sciences
Teva Pharmaceuticals
Copaxone
Idelalisib
Bristol-Myers Squibb
nivolumab
Cyramza
Eli Lilly
Pfizer
palbociclib
Sovaldi
Flag link:
3 Questions About a Big Pharma Megamerger
3 Questions About a Big Pharma Megamerger
Motley Fool
M&A
Pfizer
AstraZeneca
Big Pharma
palbociclib
Flag link:
Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race
Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race
Seeking Alpha
Novartis
Pfizer
Eli Lilly
breast cancer
palbociclib
Faslodex
AstraZeneca
LY2835219
LEE011
Flag link:
3 Breast Cancer Drugs With Big Potential
3 Breast Cancer Drugs With Big Potential
Motley Fool
breast cancer
Pfizer
Novartis
Eli Lilly
LEE011
LY2835219
palbociclib
CDK 4/6 inhibitors
Flag link:
Pfizer Breast Cancer Drug Helps Revive Discarded Strategy
Pfizer Breast Cancer Drug Helps Revive Discarded Strategy
Bloomberg
Pfizer
Eli Lilly
palbociclib
Novartis
bemaciclib
breast cancer
CDK 4/6 inhibitors
Flag link:

Pages